Cargando…
Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
INTRODUCTION: Tyrosine-kinase inhibitors (TKIs) have become the standard treatment for patients with advanced gastrointestinal stromal tumor (GIST); however, secondary mutations can still drive disease progression. Studies have shown that ripretinib, a novel switch-control TKI, inhibits various prim...
Autores principales: | Zhang, Xinhua, Zhang, Peng, Qiu, Haibo, Fang, Yong, Liu, Heli, Zhou, Yongjian, Xu, Hao, Yu, JiRen, Zhang, Jun, Wang, Ming, Shen, Lin, Li, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427548/ https://www.ncbi.nlm.nih.gov/pubmed/37356078 http://dx.doi.org/10.1007/s12325-023-02576-0 |
Ejemplares similares
-
Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study
por: Yang, Weili, et al.
Publicado: (2023) -
Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020) -
Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020) -
Ripretinib for gastrointestinal stromal tumours
Publicado: (2021) -
Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
por: Li, Jian, et al.
Publicado: (2022)